• Jung Hye Kwon, Kimberson Tanco, David Hui, Akhila Reddy, and Eduardo Bruera.
• Division of Hemato-oncology,Department of Internal Medicine,Kangdong Sacred Heart Hospital, Hallym University College of Medicine,Seoul,Republic of Korea.
• Palliat Support Care. 2014 Oct 1; 12 (5): 413-7.

ObjectiveThe purpose of this case series was to describe patients with aberrant drug-related behaviors and similar patterns of dose escalation in whom interdisciplinary assessment revealed different bases for their dose increases.MethodDuring the period from December 26 to December 30, 2011, the medical records of two patients with opioid-related aberrant behaviors were reviewed.ResultsWe described two patients with a significant cancer history and different comorbidities who presented with different aberrant drug-related behaviors and opioid requirements.Significance Of ResultsOpioid-related aberrant behaviors can be interpreted in different ways, and two of the more common syndromes in cancer patients are chemical coping and pseudoaddiction. In advanced cancer patients, the boundaries between these conditions are not as clear, and diagnosis is often made retrospectively. Furthermore, there have been relatively limited studies describing these two syndromes. Thus, they continue to pose a diagnostic and treatment challenge that requires different approaches for effective management of symptoms. The key characteristic between the two syndromes is that the behaviors displayed in chemical coping are motivated by obtaining opioids to relieve psychosocial distress, while in pseudoaddiction these behaviors are motivated by uncontrolled nociceptive input. Close monitoring of the pain syndromes, aberrant behaviors, and opioid requirements over several visits is usually necessary to distinguish the two syndromes.

31 keywords...

hide…